Literature DB >> 28053212

Multilocus Phylogeny and Antifungal Susceptibility of Aspergillus Section Circumdati from Clinical Samples and Description of A. pseudosclerotiorum sp. nov.

J P Z Siqueira1,2, D A Sutton3, J Gené4, D García1, N Wiederhold3, S W Peterson5, J Guarro1.   

Abstract

A multilocus phylogenetic study was carried out to assess species identity of a set of 34 clinical isolates from Aspergillus section Circumdati from the United States and to determine their in vitro antifungal susceptibility against eight antifungal drugs. The genetic markers used were the internal transcribed spacer (ITS) region, and fragments of the beta-tubulin (BenA), calmodulin (CaM), and RNA polymerase II second largest subunit (RPB2) genes. The drugs tested were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine. The most common species sampled was A. westerdijkiae (29.4%), followed by a novel species, which was described here as A. pseudosclerotiorum (23.5%). Other species identified were A. sclerotiorum (17.6%), A. ochraceus (8.8%), A. subramanianii (8.8%), and A. insulicola and A. ochraceopetaliformis, with two isolates (5.9%) of each. The drugs that showed the most potent activity were caspofungin, micafungin, and terbinafine, while amphotericin B showed the least activity.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Aspergillus; Circumdati section; clinical isolates; molecular identification; phenotypic identification

Mesh:

Substances:

Year:  2017        PMID: 28053212      PMCID: PMC5328464          DOI: 10.1128/JCM.02012-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  48 in total

1.  Chronic monolateral otomycosis in a dog caused by Aspergillus ochraceus.

Authors:  Giovanni Ghibaudo; Andrea Peano
Journal:  Vet Dermatol       Date:  2010-04-09       Impact factor: 1.589

2.  Polyphasic taxonomy of Aspergillus fumigatus and related species.

Authors:  Seung-Beom Hong; Seung-Joo Go; Hyeon-Dong Shin; Jens C Frisvad; Robert A Samson
Journal:  Mycologia       Date:  2005 Nov-Dec       Impact factor: 2.696

3.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

4.  Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece.

Authors:  Michael Arabatzis; Manousos Kambouris; Miltiades Kyprianou; Aikaterini Chrysaki; Maria Foustoukou; Maria Kanellopoulou; Lydia Kondyli; Georgia Kouppari; Chrysa Koutsia-Karouzou; Evangelia Lebessi; Anastasia Pangalis; Efthimia Petinaki; Ageliki Stathi; Eleftheria Trikka-Graphakos; Erriketi Vartzioti; Aliki Vogiatzi; Timoleon-Achilleas Vyzantiadis; Loukia Zerva; Aristea Velegraki
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

5.  Onychomycosis from Aspergillus melleus, a Novel Pathogen for Humans. Fungal Identification and in vitro Drug Susceptibility.

Authors:  Mirca Zotti; Arianna Fay Agnoletti; Alfredo Vizzini; Emanuele Cozzani; Aurora Parodi
Journal:  Exp Dermatol       Date:  2015-08-21       Impact factor: 3.960

6.  Identification by Molecular Methods and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Antifungal Susceptibility Profiles of Clinically Significant Rare Aspergillus Species in a Referral Chest Hospital in Delhi, India.

Authors:  Aradhana Masih; Pradeep K Singh; Shallu Kathuria; Kshitij Agarwal; Jacques F Meis; Anuradha Chowdhary
Journal:  J Clin Microbiol       Date:  2016-07-13       Impact factor: 5.948

7.  Mechanism of ochratoxin A-induced immunosuppression.

Authors:  T Lea; K Steien; F C Størmer
Journal:  Mycopathologia       Date:  1989-09       Impact factor: 2.574

8.  Toxic indole alkaloids avrainvillamide and stephacidin B produced by a biocide tolerant indoor mold Aspergillus westerdijkiae.

Authors:  Raimo Mikkola; Maria A Andersson; Maria Hautaniemi; Mirja S Salkinoja-Salonen
Journal:  Toxicon       Date:  2015-03-21       Impact factor: 3.033

9.  Aspergillus steynii and Aspergillus westerdijkiae as potential risk of OTA contamination in food products in warm climates.

Authors:  Jessica Gil-Serna; Belén Patiño; Laura Cortes; Maria Teresa Gonzalez-Jaen; Covadonga Vazquez
Journal:  Food Microbiol       Date:  2014-07-27       Impact factor: 5.516

10.  Sclerotiamide: a new member of the paraherquamide class with potent antiinsectan activity from the sclerotia of Aspergillus sclerotiorum.

Authors:  A C Whyte; J B Gloer; D T Wicklow; P F Dowdw
Journal:  J Nat Prod       Date:  1996-11       Impact factor: 4.050

View more
  5 in total

Review 1.  Name Changes for Fungi of Medical Importance, 2016-2017.

Authors:  David W Warnock
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

2.  In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.

Authors:  Michael A Pfaller; Paul R Rhomberg; Nathan P Wiederhold; Connie Gibas; Carmita Sanders; Hongxin Fan; James Mele; Laura L Kovanda; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

3.  Aspergillus Species in Lower Respiratory Tract of Hospitalized Patients from Shanghai, China: Species Diversity and Emerging Azole Resistance.

Authors:  Yuan Xu; Min Chen; Junhao Zhu; Bert Gerrits van den Ende; Amanda Juan Chen; Abdullah M S Al-Hatmi; Li Li; Qiangqiang Zhang; Jianping Xu; Wanqing Liao; Yuchong Chen
Journal:  Infect Drug Resist       Date:  2020-12-29       Impact factor: 4.003

Review 4.  Taxonomy and evolution of Aspergillus, Penicillium and Talaromyces in the omics era - Past, present and future.

Authors:  Chi-Ching Tsang; James Y M Tang; Susanna K P Lau; Patrick C Y Woo
Journal:  Comput Struct Biotechnol J       Date:  2018-05-31       Impact factor: 7.271

5.  In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies.

Authors:  Olga Rivero-Menendez; Juan Carlos Soto-Debran; Manuel Cuenca-Estrella; Ana Alastruey-Izquierdo
Journal:  J Fungi (Basel)       Date:  2021-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.